

## cyclin G1 Circular RNA for Cancer Vaccine Research

Catalog Number:CVAC-ORNA-0429

DESCRIPTION	
Product Name	cyclin G1 Circular RNA for Cancer Vaccine Research
Gene Name	cyclin G1
Source	In vitro transcribed mRNA was further circularized to make this product as a circular RNA.
Alternative names	Retrovector Encoding Mutant Anti-Cyclin G1
SPECIFICATIONS	
Cap	
5'-UTR	5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence
ORF	cyclin G1
3'-UTR	3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA
Poly(A) Tail	
Modifications	N1-methyl-pseudouridine
Neutral Lipid	1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
Cholesterol	Cholesterol
Lonizable Lipid	1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
PEG-lipid	Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)
Storage	-80 °C
Buffer	PBS, pH7.5
Cryoprotectant	Trehalose
BACKGROUND	
Gene Accession	
Gene Alias	Retrovector Encoding Mutant Anti-Cyclin G1

collagen of the tumor matrix because of the incorporation of the collagen-binding domain of von Willebrand factor (vWF) on the retrovector surface. Exploiting the collagen-targeting mechanism of vWF permits delivery of the retrovector to tumor sites where angiogenesis and collagen matrix exposure occur. (NCIT\_C49082).

**Background**

Description: A replication-incompetent, pathotropic, tumor matrix (collagen)-targeted, retroviral vector encoding an N-terminal deletion mutant form of the cyclin G1 gene with potential antineoplastic activity. Under the control of a hybrid long-terminal repeat/cytomegalovirus (CMV) promoter, retrovector encoding mutant anti-cyclin G expresses the mutant cyclin G1 construct, resulting in disruption of tumor cell cyclin G1 activity and decreased cellular proliferation and angiogenesis. This agent preferentially targets